PRODCUTS

连花-en.png

  • Drug Name:Lianhua Qingwen Capsules

  • Approval No.: GYZZ Z20040063

  • Strength: 0.35g/capsule

  • Administration and Dosage: For oral administration, 4 capsules once, 3 times daily.

  • Shelf-life: 30 months

  • Ingredients:Weeping Forsythia Capsule, Japanese Honeysuckle Flower, Ephedra Herb (honey-fried), Bitter Apricot Seed (stir-baked), Gypsum, Isatis Root, Male Fern Rhizome, Heartleaf Houttuynia Herb, Cablin Patchouli Herb, Rhubarb, Bigflower Rhodiola Root, Menthol,Liquorice Root. Excipient: Starch.

  • Functions and Indications:Clear heat and detoxify,remove lung hotness. Used in treatment of epidemic influenza and lung heat, symptom as fever or high fever, aversion to cold, muscular soreness,rhinostegnosis and nasal discharge, cough, headache, dry and sore throat, flushing tongue, or greasy fur of tongue.

Lianhua Qingwen, a representative TCM patent product for the treatment of influenza

The treatment of influenza using the TCM patent product Lianhua Qingwen won the Second-class Prize of the National Science and Technology Progress Award in 2011.

  • Won the Second-class Prize of the National Science and Technology Progress Award

  • Listed in the List of National Essential Drugs

  • A Class A Product in the National Health Insurance Program

  • A National Level Key New Product

  • A Key National Project for New Drug Innovation of the "Twelfth Five-Year Plan"

  • A Model High-tech Project of National Development and Reform Commission

  • Phase II Clinical Trial Underway in the US as Approved by US FDA

The pathogenesis and the treatment of influenza are investigated from the TCM point of view as guided by the collateral disease theory. A kind of treatment strategy with "Active Intervention" is proposed. Such famous recipes as the hemp apricot decoction recorded in the Treatise on Febrile Diseases of Han Dynasty, the use of rheum officinale for the treatment of epidemic diseases proposed in the Treatise on Pestilence of Ming Dynasty and the Lonicera and Forsythia Powder recorded in the Treatise on Differentiation and Treatment of Epidemic Febrile Diseases of Qing Dynasty are combined together into one recipe and it is proved to be with excellent therapeutic effects on the early symptoms of cold and influenza. It has a broad spectrum of therapeutic effects against viruses and bacteria and has such functions as anti-inflammation, fever relieving, resolving phlegm and relieving coughing. "Lianhua Qingwen is the best choice for anti-inflammation, fever relieving and anti-virus for such symptoms as headache, fever and aversion to cold and for the treatment of such diseases as cold, influenza and avian influenza". This product plays a very important role in such public health emergencies as the epidemic outbreaks of influenza, avian influenza and novel coronavirus pneumonia. It is a kind of product of reserve of the relevant national authorities.


  • 2020, recognized as a recommended product in the Standard Therapy for Novel Coronavirus Pneumonia (Version VII, Tentative)


  • 2019, recognized as a recommended product in the Standard Therapy for Influenza (2019)

  • 2018, recognized as a recommended product in the Standard Therapy for Influenza (2018, Revised)

  • 2018, recognized as a recommended product in the Standard Therapy for Influenza (2018)

  • 2017, recognized as a recommended product in Guideline for Clinical Application of TCM Patent Products · Treatment of Pediatric Diseases

  • 22017, recognized as a recommended product in the Standard Therapy for Human Beings Infected by H7N9 Avian Influenza

  • 2016, the Phase II Clinical Trial for Lianhua Qingwen approved by US FDA started in Virginia in the US in September

  • 2015, recognized as a recommended product in the Expert Consensus Document on Treatment of Cold in Special Populations

  • 2015, recognized as a recommended product in the Standard Therapy for Middle East Respiratory Syndrome

  • 2014, recognized as a recommended product in the Standard TCM Therapy for Ebola Virus Infections

  • 2014, recognized as a recommended product in the Standard Therapy for Human Beings Infected by H7N9 Avian Influenza

  • 2013, recognized as a recommended product in the Expert Consensus Document on Medical Rescuing of Human Beings Infected by H7N9 Avian Influenza

  • 2013, recognized as a recommended product in the Standard Therapy for Human Beings Infected by H7N9 Avian Influenza

  • 2012, recognized as a recommended product in the Standard TCM Therapy for Influenza B Virus Infections

  • 2011, recognized as a recommended product in the Guideline on Diagnosis and Treatment of Influenza

  • 2010, recognized as a recommended product in the Standard Therapy for Rheumatic Fever (Non-severe Community Acquired Pneumonia)

  • 2009, recognized as a recommended product in the Standard Therapy for Human Beings Infected by Influenza A H1N1

  • 2008, recognized as a recommended product in the Instructions on Use of TCM Therapies for Prevention and Treatment of Diseases after an Earthquake

  • 2008, recognized as a recommended product in the Standard Therapy for Human Beings Infected by Avian Influenza (2008)

  • 2005, recognized as a recommended product in the Standard Therapy for Human Beings Infected by Avian Influenza


    Address
    No.238 Tianshan street, East developing zone,Shijiazhuang,Hebei, China 
    Tel:
    +86-311-85901712

    Copyright:Shijiazhuang Yiling Pharmaceutical Co,Ltd. JI-ICP:12020237